Marinus Pharmaceuticals, Inc (MRNS)

Etorro trading 970x250
Marinus Pharmaceuticals, Inc (MRNS) Logo

About Marinus Pharmaceuticals, Inc

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Address: 5 Radnor Corporate Center, Radnor, PA, United States, 19087

Marinus Pharmaceuticals, Inc News and around…

Latest news about Marinus Pharmaceuticals, Inc (MRNS) common stock and company :

Noteworthy Friday Option Activity: RVLV, TRTN, MRNS
15 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Revolve Group Inc (RVLV), where a total volume of 5,551 contracts has been traded thus far today, a contract volume which is representative of approximately 555,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.1% of RVLV's average daily trading volume over the past month, of 719,710 shares..

Are Institutions Heavily Invested In Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Shares?
15 Oct, 2021 Yahoo! Finance

Every investor in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) should be aware of the most powerful shareholder...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Oct, 2021 FinancialContent

MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

The Math Shows XPH Can Go To $72
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $71.78 per unit.

Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
05 Oct, 2021 FinancialContent

Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
28 Sep, 2021 FinancialContent

Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

First Week of MRNS April 2022 Options Trading
20 Sep, 2021 FinancialContent

Investors in Marinus Pharmaceuticals Inc (MRNS) saw new options begin trading this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 206 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
20 Sep, 2021 FinancialContent

Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

Marinus Pharmaceuticals Inc Enters Oversold Territory (MRNS)
16 Sep, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
26 Aug, 2021 FinancialContent

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
25 Aug, 2021 FinancialContent

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Noteworthy Wednesday Option Activity: TXG, MRNS, X
18 Aug, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in 10x Genomics Inc (TXG), where a total volume of 5,314 contracts has been traded thus far today, a contract volume which is representative of approximately 531,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 92.5% of TXG's average daily trading volume over the past month, of 574,295 shares..

12 Health Care Stocks Moving In Wednesday's Intraday Session
18 Aug, 2021 FinancialContent

Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Marinus' Oral Ganaxolone Lowers Seizure Frequency In Genetic Disorder
18 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Inc(NASDAQ: MRNS) announced topline data from its open-label Phase 2 trial evaluating oral ganaxolone ...

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
17 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
16 Aug, 2021 Yahoo! Finance

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
10 Aug, 2021 Yahoo! Finance

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Marinus Pharmaceuticals: Q2 Earnings Insights
10 Aug, 2021 FinancialContent

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q2 results. Quarterly ...

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
10 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Earnings Scheduled For August 10, 2021
10 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its ...

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
08 Aug, 2021 FinancialContent

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Analysts Predict 25% Gains Ahead For The Holdings of FDM
06 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $75.32 per unit.

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
03 Aug, 2021 FinancialContent

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Noteworthy Tuesday Option Activity: HLT, CDAY, MRNS
03 Aug, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hilton Worldwide Holdings Inc (HLT), where a total of 19,092 contracts have traded so far, representing approximately 1.9 million underlying shares. That amounts to about 83.5% of HLT's average daily trading volume over the past month of 2.3 million shares..

Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion
03 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Inc(NASDAQ: MRNS)has submitted a marketing applicationto the FDA seeking approval for its ...

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
03 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
03 Aug, 2021 FinancialContent

Marinus Pharmaceuticals Submits New Drug Application to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc (MRNS) is a NASDAQ Common Stock listed in , ,

970x250